INTRODUCTION AND OBJECTIVES: Among men with localized high-risk prostate cancer (PCa), patients who met very-high-risk (VHR) criteria were shown to experience inferior outcomes after radical prostatectomy (RP) in a previous single institution study. Using a multiinstitutional dataset, here we compared pathologic and oncologic outcomes between men with high-risk and VHR PCa who underwent RP between 2005-2015. METHODS: High-risk PCa was defined as biopsy Gleason pattern 8-10, PSA >20 ng/ml, or clinical stage T3-4. VHR PCa was defined according to pre-treatment criteria: primary Gleason pattern 5 on biopsy; or ¼ 5 cores containing Gleason sum 8-10; or multiple high-risk features. Pathologic outcomes by risk classification were compared using Chi-squared testing, and oncologic outcomes (biochemical recurrence -BCR, metastasis -METS, cancer specific mortality -CSM, and overall mortality -OM) were assessed using Cox proportional hazards models. Multivariable models included age, race, institution, and neoadjuvant androgen deprivation therapy as covariates.
RESULTS: Among 1776 high-risk patients, 547 (30.8%) met VHR criteria. As compared to the high-risk cohort, VHR men had inferior pathologic outcomes. Positive margins: 38% vs 25%. Stage pT3b-4: 46% vs 17%. Stage pN1: 41% vs 15%. (P<0.001 for all comparisons). Over a median follow-up of 3 years, VHR PCa patients also had higher adjusted hazard ratios for BCR (2.32), METS (3.87), CSM (4.14), and OM (2.66). (P<0.001 for all comparisons).
CONCLUSIONS: In a multi-institutional experience of 1776 men who underwent treatment for high-risk PCa over a 10-year period, VHR cancer was strongly associated with adverse pathologic and oncologic outcomes as compared to high-risk disease. These findings serve to validate the prognostic significance of VHR PCa as a distinct entity from high-risk PCa, suggesting that VHR criteria should be considered during patient counseling and as a potential risk stratification tool in clinical trials. INTRODUCTION AND OBJECTIVES: Prostate-specific antigen doubling time (PSADT) is a useful marker for assessing disease aggressiveness at multiple stages of prostate cancer. However, in men with non-metastatic castration resistant prostate cancer (M0 CRPC), there are no commonly used PSADT cut-points for risk stratification. We examined whether PSADT correlates with metastases, all-cause mortality (ACM), and prostate cancer-specific mortality (PCSM) and identified PSADT cut-points that can be used clinically for risk stratification in men with M0 CRPC.
METHODS: We collected data on 441 men with M0 CRPC in 2000-2015 at five Veterans Affairs hospitals. Cox models were used to test the association between log-transformed PSADT and development of metastasis, ACM, and PCSM. To identify cut-points, we categorized PSADT into groups of every 3 months (<3, 3-5.9, 6-8.9, 9-11.9, 12-14.9, 15-17.9, 18-20.9, 21-23.9, 24-119.9, 120) and then combined groups with similar hazard ratios. We tested the association between PSADT cut-points and each outcome using Cox models and compared survival using Kaplan-Meier estimates.
RESULTS: Median age was 77 months (IQR: 70-83) and 160 (36%) men were black. Median PSADT was 13.3 months (IQR: 6.4-94.3) and median follow-up was 28.3 months (IQR: 14.7-49.1). As a continuous variable, PSADT was associated with metastases, ACM, and PCSM (HR 1.40-1.68, all p<0.001). We identified the PSADT cutpoints <3, 3-8.9, 9-14.9, 15 months. As a categorical variable, PSADT was associated with metastases, ACM, and PCSM (all p<0.001). Men e246 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
